

# Xingui Tian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9723688/publications.pdf>

Version: 2024-02-01

54  
papers

990  
citations

516710

16  
h-index

477307

29  
g-index

58  
all docs

58  
docs citations

58  
times ranked

1065  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology and clinical presentation of the four human parainfluenza virus types. <i>BMC Infectious Diseases</i> , 2013, 13, 28.	2.9	116
2	Epidemiology of Acute Respiratory Infections in Children in Guangzhou: A Three-Year Study. <i>PLoS ONE</i> , 2014, 9, e96674.	2.5	89
3	Human adenovirus type 7 infection causes a more severe disease than type 3. <i>BMC Infectious Diseases</i> , 2019, 19, 36.	2.9	75
4	Detection of human bocavirus from children and adults with acute respiratory tract illness in Guangzhou, southern China. <i>BMC Infectious Diseases</i> , 2011, 11, 345.	2.9	49
5	Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. <i>Vaccine</i> , 2009, 27, 1145-1153.	3.8	44
6	Comparative genomic analysis of two strains of human adenovirus type 3 isolated from children with acute respiratory infection in southern China. <i>Journal of General Virology</i> , 2006, 87, 1531-1541.	2.9	42
7	Serotype-Specific Neutralizing Antibody Epitopes of Human Adenovirus Type 3 (HAdV-3) and HAdV-7 Reside in Multiple Hexon Hypervariable Regions. <i>Journal of Virology</i> , 2012, 86, 7964-7975.	3.4	38
8	Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. <i>Virus Research</i> , 2011, 160, 214-220.	2.2	33
9	Retrospective study of adenovirus in autopsied pulmonary tissue of pediatric fatal pneumonia in South China. <i>BMC Infectious Diseases</i> , 2008, 8, 122.	2.9	32
10	Vaccine development for human mastadenovirus. <i>Journal of Thoracic Disease</i> , 2018, 10, S2280-S2294.	1.4	32
11	Protection against Enterovirus 71 with Neutralizing Epitope Incorporation within Adenovirus Type 3 Hexon. <i>PLoS ONE</i> , 2012, 7, e41381.	2.5	31
12	New Epidemiological and Clinical Signatures of 18 Pathogens from Respiratory Tract Infections Based on a 5-Year Study. <i>PLoS ONE</i> , 2015, 10, e0138684.	2.5	27
13	A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55. <i>Vaccine</i> , 2018, 36, 2199-2206.	3.8	27
14	Characterization of a cross-reactive monoclonal antibody against Norovirus genogroups I, II, III and V. <i>Virus Research</i> , 2010, 151, 142-147.	2.2	24
15	Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-8.	6.5	24
16	Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity. <i>Virology</i> , 2018, 518, 272-283.	2.4	20
17	A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55. <i>Antiviral Research</i> , 2018, 154, 17-25.	4.1	16
18	Broadly neutralizing monoclonal antibodies against human adenovirus types 55, 14p, 7, and 11 generated with recombinant type 11 fiber knob. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-12.	6.5	16

#	ARTICLE	IF	CITATIONS
19	Generation of Neutralizing Monoclonal Antibodies against a Conformational Epitope of Human Adenovirus Type 7 (HAdv-7) Incorporated in Capsid Encoded in a HAdv-3-Based Vector. <i>PLoS ONE</i> , 2014, 9, e103058.	2.5	15
20	Identification and characterization of a native epitope common to norovirus strains GII/4, GII/7 and GII/8. <i>Virus Research</i> , 2009, 140, 188-193.	2.2	14
21	Identification and Application of Neutralizing Epitopes of Human Adenovirus Type 55 Hexon Protein. <i>Viruses</i> , 2015, 7, 5632-5642.	3.3	14
22	Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China. <i>Journal of Thoracic Disease</i> , 2016, 8, 803-812.	1.4	13
23	Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China. <i>Virologica Sinica</i> , 2021, 36, 373-381.	3.0	13
24	Analysis of severe human adenovirus infection outbreak in Guangdong Province, southern China in 2019. <i>Virologica Sinica</i> , 2022, 37, 331-340.	3.0	12
25	Identification of a Critical and Conformational Neutralizing Epitope in Human Adenovirus Type 4 Hexon. <i>Journal of Virology</i> , 2018, 92, .	3.4	11
26	Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon. <i>PLoS ONE</i> , 2016, 11, e0156984.	2.5	10
27	Epidemiology and Genetic Variabilities of Human Adenovirus Type 55 Reveal Relative Genome Stability Across Time and Geographic Space in China. <i>Frontiers in Microbiology</i> , 2020, 11, 606195.	3.5	10
28	Chinese tree shrew: a permissive model for in vitro and in vivo replication of human adenovirus species B. <i>Emerging Microbes and Infections</i> , 2021, 10, 424-438.	6.5	9
29	Evaluation of an innovative pediatric isolation (PI) bed using fluid dynamics simulation and aerosol isolation efficacy. <i>Building Simulation</i> , 2021, 14, 1543-1552.	5.6	9
30	Epitope mapping of severe acute respiratory syndrome-related coronavirus nucleocapsid protein with a rabbit monoclonal antibody. <i>Virus Research</i> , 2021, 300, 198445.	2.2	9
31	Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon. <i>Virus Research</i> , 2014, 183, 67-74.	2.2	8
32	Neutralizing epitopes mapping of human adenovirus type 14 hexon. <i>Vaccine</i> , 2015, 33, 6659-6665.	3.8	8
33	A recombinant replication-defective human adenovirus type 3: A vaccine candidate. <i>Vaccine</i> , 2009, 27, 116-122.	3.8	7
34	Epitope mapping and cross-reactivity analysis of the monoclonal antibodies against hexon protein of human adenovirus type 3. <i>Virus Research</i> , 2009, 146, 58-65.	2.2	7
35	Epitope mapping and characterization of a neutralizing monoclonal antibody against human adenovirus type 3. <i>Virus Research</i> , 2013, 177, 189-193.	2.2	7
36	Analysis and solution of false-positives when testing CVA16 sera using an antibody assay against the EV71 virus. <i>Virus Research</i> , 2013, 176, 33-36.	2.2	6

#	ARTICLE	IF	CITATIONS
37	Mapping the epitope of neutralizing monoclonal antibodies against human adenovirus type 3. <i>Virus Research</i> , 2015, 208, 66-72.	2.2	6
38	Identification of adenovirus neutralizing antigens using capsid chimeric viruses. <i>Virus Research</i> , 2018, 256, 100-106.	2.2	6
39	Establishment and evaluation of a 30-minute detection method for SARS-CoV-2 nucleic acid using a novel ultra-fast real-time PCR instrument. <i>Journal of Thoracic Disease</i> , 2021, 13, 6866-6875.	1.4	6
40	Complete genome analysis of a novel E3-partial-deleted human adenovirus type 7 strain isolated in Southern China. <i>Virology Journal</i> , 2011, 8, 91.	3.4	5
41	Characterization of malleability and immunological properties of human adenovirus type 3 hexon hypervariable region 1. <i>Archives of Virology</i> , 2012, 157, 1709-1718.	2.1	5
42	Characterization of a replication-competent vector encoding DsRed based on a human adenovirus type 4 a-like strain. <i>Virus Research</i> , 2019, 270, 197662.	2.2	5
43	A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice. <i>Journal of Virology</i> , 2021, 95, .	3.4	5
44	A 10-Day-Old Murine Model of Coxsackievirus A6 Infection for the Evaluation of Vaccines and Antiviral Drugs. <i>Frontiers in Immunology</i> , 2021, 12, 665197.	4.8	5
45	Antigenic variability among two subtypes of human adenovirus serotype 7. <i>Virus Genes</i> , 2014, 49, 22-29.	1.6	4
46	Molecular evolution of human adenovirus type 16 through multiple recombination events. <i>Virus Genes</i> , 2019, 55, 769-778.	1.6	4
47	Design of an air isolation and purification (AIP) desk for medical use and characterization of its efficacy in ambient air isolation and purification. <i>Biosafety and Health</i> , 2020, 2, 169-176.	2.7	4
48	Development of two antigen-binding fragments to a conserved linear epitope of human adenovirus and their application in immunofluorescence. <i>PLoS ONE</i> , 2019, 14, e0219091.	2.5	3
49	An oral vaccine against CVA16 (Coxsackievirus A16) was developed by constructing a recombinant <i>Lactococcus lactis</i> . <i>Tropical Journal of Pharmaceutical Research</i> , 2020, 19, 927-932.	0.3	3
50	Infection and replication of human adenovirus type 3 possessing type 5 fiber protein in rodent cells. <i>Virus Research</i> , 2020, 279, 197886.	2.2	3
51	A novel method to diagnose the infection of enterovirus A71 in children by detecting IgA from saliva. <i>Journal of Medical Virology</i> , 2020, 92, 1059-1064.	5.0	2
52	A Sensitive and High-Throughput Flow Cytometry-Based Assay for Measuring Antibody Neutralization of Human Adenovirus Type 3. <i>Virologica Sinica</i> , 2021, 36, 537-544.	3.0	1
53	Design a pediatric isolation bed and characterization of its purification efficacy in ambient air. <i>Biosafety and Health</i> , 2021, 3, 172-172.	2.7	0
54	Similarity measurements of B cell receptor repertoire in baseline mice showed spectrum convergence of IgM. <i>BMC Immunology</i> , 2022, 23, 11.	2.2	0